期刊
BIOANALYSIS
卷 11, 期 15, 页码 1405-1418出版社
FUTURE SCI LTD
DOI: 10.4155/bio-2019-0163
关键词
Alzheimer's disease (AD); amyotrophic lateral sclerosis (ALS); biomarker; cerebrospinal fluid (CSF); multiple sclerosis (MS); neurodegeneration; neurofilament light (NfL) chain; Quanterix Simoa (TM); UmanDiagnostics Nf-Light ELISA (Uman ELISA)
资金
- Genentech, Inc.
Background: Neurofilament light (NfL) chain is an established cerebrospinal fluid (CSF) biomarker for neuroaxonal injury. The highly sensitive Quanterix SimoaT platform is evaluated for NfLmeasurement in both CSF and blood. There is a need to link historical ELISA data that use bovine NfL to that of Simoa using a recombinant human (rhuman) NfL standard. Results/Methodology: The Simoa NF-light (R) Advantage Kit was validated for CSF and qualified for serum and plasma, using both rhuman and bovine NfL calibrators. Matched CSF, serum and plasma samples from 112 multiple sclerosis patients were analyzed using both calibrators. Conclusion: In multiple sclerosis, there is a good correlation between blood and CSF NfL levels. A conversion factor of approximately 5:1 was established between bovine and rhuman NfL calibrators.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据